放射免疫疗法
镭-223
癌症研究
医学
靶向治疗
前列腺癌
治疗指标
体内
单克隆抗体
癌症
药理学
免疫学
抗体
内科学
生物
骨转移
药品
生物技术
作者
Viviana Frantellizzi,Laura Cosma,Gabriele Brunotti,Arianna Pani,Angela Spanu,Susanna Nuvoli,Flaminia De Cristofaro,Liana Civitelli,Giuseppe De Vincentis
出处
期刊:Cancer Biotherapy and Radiopharmaceuticals
[Mary Ann Liebert]
日期:2020-08-01
卷期号:35 (6): 437-445
被引量:32
标识
DOI:10.1089/cbr.2019.3105
摘要
Targeted alpha therapy (TAT) can deliver high localized burden of radiation selectively to cancer cells as well as the tumor microenvironment, while minimizing toxicity to normal surrounding cell. Radium-223 (223Ra), the first-in-class α-emitter approved for bone metastatic castration-resistant prostate cancer has shown the ability to prolong patient survival. Targeted Thorium-227 (227Th) conjugates represent a new class of therapeutic radiopharmaceuticals for TAT. They are comprised of the α-emitter 227Th complexed to a chelator conjugated to a tumor-targeting monoclonal antibody. In this review, the authors will focus out interest on this therapeutic agent. In recent studies 227Th-labeled radioimmunoconjugates showed a relevant stability both in serum and vivo conditions with a significant antigen-dependent inhibition of cell growth. Unlike 223Ra, the parent radionuclide 227Th can form highly stable chelator complexes and is therefore amenable to targeted radioimmunotherapy. The authors discuss the future potential role of 227Th TAT in the treatment of several solid as well as hematologic malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI